Measuring Friedreich ataxia: Interrater reliability of a n

Neurology

64, 1261-1262

DOI: 10.1212/01.wnl.0000156802.15466.79

Citation Report

#	Article	IF	Citations
1	Clinical scales. , 2010, , 53-68.		0
2	Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?. Movement Disorders, 2006, 21, 1396-1403.	2.2	24
3	Measuring Friedreich ataxia: Complementary features of examination and performance measures. Neurology, 2006, 66, 1711-1716.	1.5	189
4	Pontine and cerebellar atrophy correlate with clinical disability in SCA2. Neurology, 2006, 66, 424-426.	1.5	41
5	Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology, 2006, 66, 1717-1720.	1.5	1,579
6	How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 411-413.	0.9	85
7	Validation of a neurological-exam-based rating scale (FARS) for Friedreich's ataxia. Nature Clinical Practice Neurology, 2007, 3, 138-139.	2.7	4
8	SARAâ€"a new clinical scale for the assessment and rating of ataxia. Nature Clinical Practice Neurology, 2007, 3, 136-137.	2.7	47
9	Presentation and Progression of Friedreich Ataxia and Implications for Physical Therapist Examination. Physical Therapy, 2007, 87, 1687-1696.	1.1	27
10	Coordination and Ataxia. , 2007, , 307-325.		7
11	Friedreich's Ataxia and Related DNA Loss-of-Function Disorders. , 2007, , 277-294.		3
12	Reliability and validity of the scale for the assessment and rating of ataxia: A study in 64 ataxia patients. Movement Disorders, 2007, 22, 1633-1637.	2.2	161
13	Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI. Movement Disorders, 2007, 22, 1615-1622.	2.2	45
14	The international cooperative ataxia rating scale in Machadoâ€Joseph disease. Comparison with the unified multiple system atrophy rating scale. Movement Disorders, 2007, 22, 1976-1979.	2.2	20
15	Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important?. European Journal of Neurology, 2007, 14, 1040-1047.	1.7	45
16	Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurology, The, 2007, 6, 878-886.	4.9	295
17	An update on inherited ataxias. Current Neurology and Neuroscience Reports, 2008, 8, 310-319.	2.0	10
18	Unusual familial presentation of epsilonâ€sarcoglycan gene mutation with falls and writer's cramp. Movement Disorders, 2008, 23, 1913-1915.	2.2	27

#	Article	IF	Citations
19	High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease. Movement Disorders, 2008, 23, 1916-1919.	2.2	34
20	Urinary isoprostanes in Friedreich ataxia: Lack of correlation with disease features. Movement Disorders, 2008, 23, 1920-1922.	2.2	22
21	The nociceptin/orphanin FQ (NOP) receptor antagonist Jâ€113397 enhances the effects of levodopa in the MPTPâ€lesioned nonhuman primate model of Parkinson's disease. Movement Disorders, 2008, 23, 1922-1925.	2.2	37
22	Focal childhoodâ€onset, action induced primary hip dystonia treated with pallidal deep brain stimulation. Movement Disorders, 2008, 23, 1926-1928.	2.2	8
23	Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Movement Disorders, 2008, 23, 1929-1931.	2.2	102
24	MRâ€spectroscopic findings in juvenileâ€onset Huntington's disease. Movement Disorders, 2008, 23, 1931-1935.	2.2	20
25	Balance selfâ€efficacy determines walking capacity in people with Parkinson's disease. Movement Disorders, 2008, 23, 1936-1939.	2.2	26
26	Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial. Movement Disorders, 2008, 23, 1940-1944.	2.2	89
27	Chronic acquired sensory neuron diseases. European Journal of Neurology, 2008, 15, 1400-1405.	1.7	22
28	Idebenone in Friedreich's ataxia. Expert Opinion on Pharmacotherapy, 2008, 9, 2327-2337.	0.9	36
29	Validating an Ataxia Functional Composite Scale in spinocerebellar ataxia. Journal of the Neurological Sciences, 2008, 268, 136-139.	0.3	13
30	Drug Insight: antioxidant therapy in inherited ataxias. Nature Clinical Practice Neurology, 2008, 4, 86-96.	2.7	53
31	Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain, 2008, 131, 1352-1361.	3.7	90
32	SCA Functional Index. Neurology, 2008, 71, 486-492.	1.5	127
33	Speech perception ability in individuals with Friedreich ataxia. Brain, 2008, 131, 2002-2012.	3.7	85
34	Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain, 2008, 131, 1035-1045.	3.7	125
35	Clinical features of spinal and bulbar muscular atrophy. Brain, 2009, 132, 3242-3251.	3.7	223
36	Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies. Movement Disorders, 2009, 24, 984-992.	2.2	24

#	Article	IF	Citations
37	Effectiveness and safety of treatments for degenerative ataxias: A systematic review. Movement Disorders, 2009, 24, 1111-1124.	2.2	65
38	Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Movement Disorders, 2009, 24, 1779-1784.	2.2	131
39	Evaluating the progression of Friedreich ataxia and its treatment. Journal of Neurology, 2009, 256, 36-41.	1.8	55
40	A combined voxel-based morphometry and 1H-MRS study in patients with Friedreichâ€™s ataxia. Journal of Neurology, 2009, 256, 1114-1120.	1.8	67
41	Quantitative evaluation of functional limitation of upper limb movements in subjects affected by ataxia. European Journal of Neurology, 2009, 16, 232-239.	1.7	84
42	Diagnosis and treatment of Friedreich ataxia: a European perspective. Nature Reviews Neurology, 2009, 5, 222-234.	4.9	231
43	Characterizing Gait, Locomotor Status, and Disease Severity in Children and Adolescents with Friedreich Ataxia. Journal of Neurologic Physical Therapy, 2009, 33, 144-149.	0.7	17
44	A comparison of three measures of upper limb function in Friedreich ataxia. Journal of Neurology, 2010, 257, 518-523.	1.8	29
45	Impairment in motor reprogramming in Friedreich ataxia reflecting possible cerebellar dysfunction. Journal of Neurology, 2010, 257, 782-791.	1.8	33
46	Ocular Motor Fixation Deficits in Friedreich Ataxia. Cerebellum, 2010, 9, 411-418.	1.4	27
47	Disruption to higher order processes in Friedreich ataxia. Neuropsychologia, 2010, 48, 235-242.	0.7	33
48	1H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2. Brain Research, 2010, 1358, 200-210.	1.1	37
49	Translation and validation into Brazilian version of the Scale of the Assessment and Rating of Ataxia (SARA). Arquivos De Neuro-Psiquiatria, 2010, 68, 228-230.	0.3	70
50	Friedreichâ€™s Ataxia Rating Scale (FARS). , 2010, , 497-506.		0
51	International Cooperative Ataxia Rating Scale (ICARS). , 2010, , 75-81.		2
52	Dysarthria in Friedreichâ€™s Ataxia: A Perceptual Analysis. Folia Phoniatrica Et Logopaedica, 2010, 62, 97-103.	0.5	59
53	A Phase 3, Double-blind, Placebo-Controlled Trial of Idebenone in Friedreich Ataxia. Archives of Neurology, 2010, 67, 941-7.	4.9	187
54	Successful treatment of auditory perceptual disorder in individuals with Friedreich ataxia. Neuroscience, 2010, 171, 552-555.	1.1	46

#	Article	IF	Citations
55	Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia. Archives of Physical Medicine and Rehabilitation, 2010, 91, 1044-1050.	0.5	32
56	Impaired inhibition of prepotent motor tendencies in Friedreich ataxia demonstrated by the Simon interference task. Brain and Cognition, 2011, 76, 140-145.	0.8	21
57	The Fitts task reveals impairments in planning and online control of movement in Friedreich ataxia: reduced cerebellar-cortico connectivity?. Neuroscience, 2011, 192, 382-390.	1.1	29
58	27 Extrapyramidale Syndrome und Ataxien. , 2011, , .		0
59	Cerebellar atrophy is frequently associated with non-paraneoplastic sensory neuronopathy. Arquivos De Neuro-Psiquiatria, 2011, 69, 602-606.	0.3	2
60	Autonomic dysfunction in non-paraneoplastic sensory neuronopathy: beyond sensory abnormalities. Journal of Neurology, 2011, 258, 231-237.	1.8	9
61	A novel deletionâ€“insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype. Neurogenetics, 2011, 12, 307-313.	0.7	14
62	Superior Cerebellar Peduncle Atrophy in Friedreichâ€™s Ataxia Correlates with Disease Symptoms. Cerebellum, 2011, 10, 81-87.	1.4	69
63	Utilisation of Advance Motor Information is Impaired in Friedreich Ataxia. Cerebellum, 2011, 10, 793-803.	1.4	18
64	Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Movement Disorders, 2011, 26, 534-538.	2.2	24
65	Comparison of cerebellar ataxias: A threeâ€year prospective longitudinal assessment. Movement Disorders, 2011, 26, 2081-2087.	2.2	55
66	The Test of Everyday Attention Reveals Significant Sustained Volitional Attention and Working Memory Deficits in Friedreich Ataxia. Journal of the International Neuropsychological Society, 2011, 17, 196-200.	1.2	20
67	Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. European Heart Journal, 2011, 32, 561-567.	1.0	74
68	Oculomotor and visual axis systems sparing in spinocerebellar ataxia type 13 ^{R420H}. Neurology, 2012, 79, 1181-1182.	1.5	4
69	Auditory Processing Deficits in Children With Friedreich Ataxia. Journal of Child Neurology, 2012, 27, 1197-1203.	0.7	35
70	Friedreich ataxia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 103, 275-294.	1.0	25
71	Central role and mechanisms of Î²â€cell dysfunction and death in friedreich ataxiaâ€“associated diabetes. Annals of Neurology, 2012, 72, 971-982.	2.8	84
72	Longitudinal change in dysarthria associated with Friedreich ataxia: a potential clinical endpoint. Journal of Neurology, 2012, 259, 2471-2477.	1.8	27

#	Article	IF	Citations
73	Auditory pathway changes mirror overall disease progress in individuals with Friedreich ataxia. Journal of Neurology, 2012, 259, 2746-2748.	1.8	8
74	Decreased functional brain activation in Friedreich ataxia using the Simon effect task. Brain and Cognition, 2012, 79, 200-208.	0.8	37
75	A functional MRI study of motor dysfunction in Friedreich's ataxia. Brain Research, 2012, 1471, 138-154.	1.1	35
76	A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Movement Disorders, 2012, 27, 1312-1316.	2.2	73
77	Binaural speech processing in individuals with auditory neuropathy. Neuroscience, 2012, 226, 227-235.	1.1	38
78	Objective home-based gait assessment in spinocerebellar ataxia. Journal of the Neurological Sciences, 2012, 313, 95-98.	0.3	15
79	Principal Component Analysis of Cerebellar Shape on MRI Separates SCA Types 2 and 6 into Two Archetypal Modes of Degeneration. Cerebellum, 2012, 11, 887-895.	1.4	23
80	30.7 Skalen zur Bewertung der LebensqualitÃt bei BewegungsstÃ¶rungen. , 2012, , .		0
81	FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Annals of Neurology, 2012, 71, 487-497.	2.8	101
82	MRI Shows a Region-Specific Pattern of Atrophy in Spinocerebellar Ataxia Type 2. Cerebellum, 2012, 11, 272-279.	1.4	49
83	Ataxia Rating Scalesâ€"Psychometric Profiles, Natural History and Their Application in Clinical Trials. Cerebellum, 2012, 11, 488-504.	1.4	101
84	Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity. Movement Disorders, 2012, 27, 135-139.	2.2	30
85	Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. Journal of Neurology, 2012, 259, 284-291.	1.8	88
86	Impact of Friedreichâ€™s Ataxia on health-care resource utilization in the United Kingdom and Germany. Orphanet Journal of Rare Diseases, 2013, 8, 38.	1.2	14
87	Analysis of the visual system in Friedreich ataxia. Journal of Neurology, 2013, 260, 2362-2369.	1.8	55
88	Excessive motor overflow reveals abnormal inter-hemispheric connectivity in Friedreich ataxia. Journal of Neurology, 2013, 260, 1757-1764.	1.8	1
89	Comprehensive Phenotype of the p.Arg420his Allelic Form of Spinocerebellar Ataxia Type 13. Cerebellum, 2013, 12, 932-936.	1.4	23
90	Inventory of Non-Ataxia Signs (INAS): Validation of a New Clinical Assessment Instrument. Cerebellum, 2013, 12, 418-428.	1.4	112

#	Article	IF	Citations
91	Neuroanatomical Correlates of Depression in Friedreichâ€™s Ataxia: a Voxel-Based Morphometry Study. Cerebellum, 2013, 12, 429-436.	1.4	20
92	Erythropoietin in <scp>F</scp>riedreich ataxia. Journal of Neurochemistry, 2013, 126, 80-87.	2.1	23
93	Spinal Cord Atrophy Correlates with Disability in Friedreichâ€™s Ataxia. Cerebellum, 2013, 12, 43-47.	1.4	37
94	Rating disease progression of Friedreichâ€™s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain, 2013, 136, 259-268.	3.7	48
95	Increased prevalence of sleep-disordered breathing in Friedreich ataxia. Neurology, 2013, 81, 46-51.	1.5	20
96	Treatment of Friedreich's ataxia. Expert Opinion on Orphan Drugs, 2013, 1, 221-234.	0.5	7
97	Monitoring progression in Friedreich ataxia (<scp>FRDA</scp>): the use of clinical scales. Journal of Neurochemistry, 2013, 126, 118-124.	2.1	51
99	Rehabilitation of Friedreich ataxia. , 0, , 185-202.		1
100	Sensitivity of Spatiotemporal Gait Parameters in Measuring Disease Severity in Friedreich Ataxia. Cerebellum, 2014, 13, 677-688.	1.4	26
101	Genetic Cerebellar Ataxias. Seminars in Neurology, 2014, 34, 280-292.	0.5	43
102	Cerebellar pathology in Friedreich's ataxia: Atrophied dentate nuclei with normal iron content. NeuroImage: Clinical, 2014, 6, 93-99.	1.4	56
103	Treatment of cerebellar ataxia. Neurodegenerative Disease Management, 2014, 4, 379-392.	1.2	8
104	Prospective study of activities of daily living outcomes in children with cerebellar atrophy. Developmental Medicine and Child Neurology, 2014, 56, 460-467.	1.1	3
105	Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia. Movement Disorders, 2014, 29, 935-939.	2.2	46
106	Deep Learning for Cerebellar Ataxia ClassificationÂandÂFunctionalÂScoreÂRegression. Lecture Notes in Computer Science, 2014, 8679, 68-76.	1.0	23
107	Assessing Function and Endurance in Adults with Spinal and Bulbar Muscular Atrophy: Validity of the Adult Myopathy Assessment Tool. Rehabilitation Research and Practice, 2014, 2014, 1-16.	0.5	28
108	Atypical Friedreich ataxia in patients with FXN p.R165P point mutation or comorbid hemochromatosis. Parkinsonism and Related Disorders, 2014, 20, 919-923.	1.1	10
109	Friedreich Ataxia: Executive Control Is Related to Disease Onset and GAA Repeat Length. Cerebellum, 2014, 13, 9-16.	1.4	20

#	Article	IF	Citations
110	Cerebello-cerebral connectivity deficits in Friedreich ataxia. Brain Structure and Function, 2014, 219, 969-981.	1.2	44
111	Cognitive Deficits In Friedreich Ataxia Correlate with Micro-structural Changes in Dentatorubral Tract. Cerebellum, 2014, 13, 187-198.	1.4	40
112	Dysphagia and swallowing-related quality of life in Friedreich ataxia. Journal of Neurology, 2014, 261, 392-399.	1.8	20
113	Consensus Paper: Management of Degenerative Cerebellar Disorders. Cerebellum, 2014, 13, 248-268.	1.4	166
114	Dentate nuclei T2 relaxometry is a reliable neuroimaging marker in Friedreich's ataxia. European Journal of Neurology, 2014, 21, 1131-1136.	1.7	42
115	Deferiprone in <scp>F</scp>riedreich ataxia: A 6â€Month randomized controlled trial. Annals of Neurology, 2014, 76, 509-521.	2.8	109
116	Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration. Journal of Neurology, 2014, 261, 1381-1386.	1.8	6
117	Saccade reprogramming in Friedreich ataxia reveals impairments in the cognitive control of saccadic eye movement. Brain and Cognition, 2014, 87, 161-167.	0.8	6
118	Cross-sectional analysis of glucose metabolism in Friedreich Ataxia. Journal of the Neurological Sciences, 2014, 342, 29-35.	0.3	16
119	Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited. Journal of the Neurological Sciences, 2014, 341, 64-67.	0.3	11
120	Myelin paucity of the superior cerebellar peduncle in individuals with Friedreich ataxia: an MRI magnetization transfer imaging study. Journal of the Neurological Sciences, 2014, 343, 138-143.	0.3	21
121	The absence of curly hair is associated with a milder phenotype in Giant Axonal Neuropathy. Neuromuscular Disorders, 2014, 24, 48-55.	0.3	16
122	Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet, The, 2014, 384, 504-513.	6.3	129
123	Robotic and clinical evaluation of upper limb motor performance in patients with Friedreichâ€™s Ataxia: an observational study. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 41.	2.4	42
124	Clinical Scales Predict Significant Videofluoroscopic Dysphagia in Machado Joseph Disease Patients. Movement Disorders Clinical Practice, 2015, 2, 260-266.	0.8	5
125	Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials. , 2015, , .		5
126	MRI Texture Analysis Reveals Bulbar Abnormalities in Friedreich Ataxia. American Journal of Neuroradiology, 2015, 36, 2214-2218.	1.2	19
127	Towards neurobehavioral biomarkers for longitudinal monitoring of neurodegeneration with wearable body sensor networks. , 2015, , .		5

#	Article	IF	Citations
128	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurology, The, 2015, 14, 174-182.	4.9	159
129	Quantifiable evaluation of cerebellar signs in children. Neurology, 2015, 84, 1225-1232.	1.5	8
130	Nasality in Friedreich ataxia. Clinical Linguistics and Phonetics, 2015, 29, 46-58.	0.5	18
131	A study of up to 12â€…years of follow-up of Friedreich ataxia utilising four measurement tools. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 660-666.	0.9	22
132	A longitudinal study of the Friedreich Ataxia Impact Scale. Journal of the Neurological Sciences, 2015, 352, 53-57.	0.3	17
133	Clinical Evaluation of Eye Movements in Spinocerebellar Ataxias. Journal of Neuro-Ophthalmology, 2015, 35, 16-21.	0.4	54
134	An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of Neurology, 2015, 262, 1344-1353.	1.8	89
135	Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurologica Scandinavica, 2015, 132, 7-15.	1.0	49
136	A toolbox to visually explore cerebellar shape changes in cerebellar disease and dysfunction. Proceedings of SPIE, 2016, 9785, .	0.8	0
137	Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. Journal of Child Neurology, 2016, 31, 1036-1040.	0.7	45
138	Fronto-cerebellar dysfunction and dysconnectivity underlying cognition in friedreich ataxia: The IMAGE-FRDA study. Human Brain Mapping, 2016, 37, 338-350.	1.9	47
139	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. Contemporary Clinical Neuroscience, 2016, , .	0.3	3
140	Magnetic Resonance Spectroscopy in Ataxias. Contemporary Clinical Neuroscience, 2016, , 179-200.	0.3	2
141	Cerebral and cerebellar greyÂmatter atrophy in Friedreich ataxia: the IMAGE-FRDA study. Journal of Neurology, 2016, 263, 2215-2223.	1.8	49
142	Ataxia Scales for the Clinical Evaluation. , 2016, , 513-520.		4
143	Progression of Friedreich ataxia: quantitative characterization over 5 years. Annals of Clinical and Translational Neurology, 2016, 3, 684-694.	1.7	117
144	Progression characteristics of the European Friedreichâ€™s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurology, The, 2016, 15, 1346-1354.	4.9	117
145	Standardized Assessment of Hereditary Ataxia Patients in Clinical Studies. Movement Disorders Clinical Practice, 2016, 3, 230-240.	0.8	13

#	Article	IF	Citations
146	Interferon gamma may improve cardiac function in Friedreich's ataxia cardiomyopathy. International Journal of Cardiology, 2016, 221, 376-378.	0.8	8
147	Emerging therapies in Friedreich's ataxia. Neurodegenerative Disease Management, 2016, 6, 49-65.	1.2	55
148	Gastrocnemius and soleus spasticity and muscle length in Friedreichâ€™s ataxia. Journal of Clinical Neuroscience, 2016, 29, 29-34.	0.8	5
149	Longitudinal magnetic resonance imaging study shows progressive pyramidal and callosal damage in Friedreich's ataxia. Movement Disorders, 2016, 31, 70-78.	2.2	45
150	GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNÎ³ administration in FRDA patients. Neurological Sciences, 2016, 37, 361-364.	0.9	24
151	Measuring Inhibition and Cognitive Flexibility in Friedreich Ataxia. Cerebellum, 2017, 16, 757-763.	1.4	15
152	Dysphagia in Friedreich Ataxia. Dysphagia, 2017, 32, 626-635.	1.0	15
153	Structural signature of classical versus lateâ€onset friedreich's ataxia by Multimodality brain M<scp>RI</scp>. Human Brain Mapping, 2017, 38, 4157-4168.	1.9	13
154	Cerebral compensation during motor function in Friedreich ataxia: The IMAGEâ€FRDA study. Movement Disorders, 2017, 32, 1221-1229.	2.2	24
155	Longitudinal gait and balance decline in Friedreichâ€™s Ataxia: A pilot study. Gait and Posture, 2017, 55, 25-30.	0.6	14
156	Mitochondrial capacity, muscle endurance, and low energy in friedreich ataxia. Muscle and Nerve, 2017, 56, 773-779.	1.0	25
157	Structural cerebellar correlates of cognitive and motor dysfunctions in cerebellar degeneration. Brain, 2017, 140, aww327.	3.7	84
158	Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Review of Neurotherapeutics, 2017, 17, 895-907.	1.4	63
159	Impact of diabetes in the Friedreich ataxia clinical outcome measures study. Annals of Clinical and Translational Neurology, 2017, 4, 622-631.	1.7	16
160	How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?. Journal of Neurology, 2017, 264, 1768-1776.	1.8	9
161	A longitudinal study of the SF-36 version 2 in Friedreich ataxia. Acta Neurologica Scandinavica, 2017, 136, 41-46.	1.0	7
162	Glutathione as a Redox Biomarker in Mitochondrial Diseaseâ€”Implications for Therapy. Journal of Clinical Medicine, 2017, 6, 50.	1.0	64
163	Clinical Trials in Mitochondrial Disease. FIRE Forum for International Research in Education, 2017, 5, 232640981773301.	0.7	17

#	Article	IF	Citations
164	Urinary, bowel and sexual symptoms in a cohort of patients with Friedreichâ€™s ataxia. Orphanet Journal of Rare Diseases, 2017, 12, 158.	1.2	15
165	International Cooperative Ataxia Rating Scale (ICARS)â˜†. , 2017, , .		0
166	Progress in the treatment of Friedreich ataxia. Neurologia I Neurochirurgia Polska, 2018, 52, 129-139.	0.6	32
167	Impact of Mobility Device Use on Quality of Life in Children With Friedreich Ataxia. Journal of Child Neurology, 2018, 33, 397-404.	0.7	5
168	Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Annals of Neurology, 2018, 83, 816-829.	2.8	71
169	Psychometric properties of outcome measures evaluating decline in gait in cerebellar ataxia: A systematic review. Gait and Posture, 2018, 61, 149-162.	0.6	18
170	Emerging therapeutics for the treatment of Friedreichâ€™s ataxia. Expert Opinion on Orphan Drugs, 2018, 6, 57-67.	0.5	12
171	Can rehabilitation improve the health and well-being in Friedreichâ€™s ataxia: a randomized controlled trial?. Clinical Rehabilitation, 2018, 32, 630-643.	1.0	21
172	Cerebral abnormalities in Friedreich ataxia: A review. Neuroscience and Biobehavioral Reviews, 2018, 84, 394-406.	2.9	45
173	Automated functional upper limb evaluation of patients with Friedreich ataxia using serious games rehabilitation exercises. Journal of NeuroEngineering and Rehabilitation, 2018, 15, 87.	2.4	22
174	Corneal confocal microscopy: Neurologic disease biomarker in Friedreich ataxia. Annals of Neurology, 2018, 84, 893-904.	2.8	31
175	Functional and Structural Brain Damage in Friedreich's Ataxia. Frontiers in Neurology, 2018, 9, 747.	1.1	25
176	Autonomic function testing in Friedreichâ€™s ataxia. Journal of Neurology, 2018, 265, 2015-2022.	1.8	14
177	Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia. Neurodegenerative Disease Management, 2018, 8, 233-242.	1.2	62
178	Scales for the clinical evaluation of cerebellar disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 154, 329-339.	1.0	20
179	Measuring peripheral nerve involvement in Friedreichâ€™s ataxia. Annals of Clinical and Translational Neurology, 2019, 6, 1718-1727.	1.7	12
180	The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C. Cerebellum and Ataxias, 2019, 6, 9.	1.9	9
181	New developments in pharmacotherapy for Friedreich ataxia. Expert Opinion on Pharmacotherapy, 2019, 20, 1855-1867.	0.9	34

#	Article	IF	Citations
182	Sensory ataxia rating scale: Development and validation of a functional scale for patients with sensory neuronopathies. Journal of the Peripheral Nervous System, 2019, 24, 242-246.	1.4	5
183	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 2019, 1, 33.	1.0	14
184	An Instrumented Measurement Scheme for the Assessment of Upper Limb Function in Individuals with Friedreich Ataxia. , 2019, 2019, 317-320.		5
185	Changes detected in swallowing function in Friedreich ataxia over 12 months. Neuromuscular Disorders, 2019, 29, 786-793.	0.3	5
186	Altered neocortical tactile but preserved auditory early change detection responses in Friedreich ataxia. Clinical Neurophysiology, 2019, 130, 1299-1310.	0.7	13
187	Openâ€label pilot study of oral methylprednisolone for the treatment of patients with friedreich ataxia. Muscle and Nerve, 2019, 60, 571-575.	1.0	8
188	Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?. Frontiers in Neuroscience, 2019, 13, 386.	1.4	8
189	Probing the multifactorial source of hand dysfunction in Friedreich ataxia. Journal of Clinical Neuroscience, 2019, 64, 71-76.	0.8	6
190	Psychometric properties of the Friedreich Ataxia Rating Scale. Neurology: Genetics, 2019, 5, 371.	0.9	57
191	Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in friedreich ataxia. Movement Disorders, 2019, 34, 335-343.	2.2	53
192	Developmental and neurodegenerative damage in Friedreich's ataxia. European Journal of Neurology, 2019, 26, 483-489.	1.7	32
193	Temporal but not spatial dysmetria relates to disease severity in FA. Journal of Neurophysiology, 2020, 123, 718-725.	0.9	3
194	Multiple mechanisms underpin cerebral and cerebellar white matter deficits in Friedreich ataxia: The IMAGEâ€FRDA study. Human Brain Mapping, 2020, 41, 1920-1933.	1.9	22
195	Longitudinal Increases in Cerebral Brain Activation During Working Memory Performance in Friedreich Ataxia: 24-Month Data from IMAGE-FRDA. Cerebellum, 2020, 19, 182-191.	1.4	5
196	Central Nervous System Therapeutic Targets in Friedreich Ataxia. Human Gene Therapy, 2020, 31, 1226-1236.	1.4	26
197	Evaluation of upper limb function with digitizing tablet-based tests: reliability and discriminative validity in healthy persons and patients with neurological disorders. Disability and Rehabilitation, 2022, 44, 1465-1473.	0.9	9
198	Antioxidant Therapies and Oxidative Stress in Friedreichâ€™s Ataxia: The Right Path or Just a Diversion?. Antioxidants, 2020, 9, 664.	2.2	13
199	Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA. Frontiers in Neurology, 2020, 11, 902.	1.1	26

#	Article	IF	Citations
200	Testâ€“retest reliability of the Friedreichâ€™s ataxia rating scale. Annals of Clinical and Translational Neurology, 2020, 7, 1708-1712.	1.7	12
201	Vestibular impact of Friedreich ataxia in early onset patients. Cerebellum and Ataxias, 2020, 7, 6.	1.9	7
202	Cerebellar cognitive disorder parallels cerebellar motor symptoms in Friedreich ataxia. Annals of Clinical and Translational Neurology, 2020, 7, 1050-1054.	1.7	32
203	Assessment of Cerebral and Cerebellar White Matter Microstructure in Spinocerebellar Ataxias 1, 2, 3, and 6 Using Diffusion MRI. Frontiers in Neurology, 2020, 11, 411.	1.1	16
204	The Assessment of Upper Limb Functionality in Friedreich Ataxia via Self-Feeding Activity. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2020, 28, 924-933.	2.7	15
205	Predictors of loss of ambulation in Friedreich's ataxia. EClinicalMedicine, 2020, 18, 100213.	3.2	40
206	Scoping review of symptoms in children with rare, progressive, life-threatening disorders. BMJ Supportive and Palliative Care, 2020, 10, 91-104.	0.8	10
207	Neurologic outcomes in Friedreich ataxia. Neurology: Genetics, 2020, 6, e415.	0.9	27
208	Safety and efficacy of (+)â€epicatechin in subjects with Friedreich's ataxia: A phase <scp>II</scp>, openâ€label, prospective study. Journal of Inherited Metabolic Disease, 2021, 44, 502-514.	1.7	15
209	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Movement Disorders, 2021, 36, 283-297.	2.2	52
210	Developing an Instrumented Measure of Upper Limb Function in Friedreich Ataxia. Cerebellum, 2021, 20, 430-438.	1.4	4
211	Gauging Gait Disorders with a Method Inspired by Motor Control Theories: A Pilot Study in Friedreichâ€™s Ataxia. Sensors, 2021, 21, 1144.	2.1	3
212	Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG). Cerebellum, 2021, 20, 596-605.	1.4	8
213	Discordance Between Patient-Reported Outcomes and Physician-Rated Motor Symptom Severity in Early-to-Middle-Stage Spinocerebellar Ataxia Type 3. Cerebellum, 2021, 20, 887-895.	1.4	12
214	Pre-clinical left ventricular myocardial remodeling in patients with Friedreichâ€™s ataxia: A cardiac MRI study. PLoS ONE, 2021, 16, e0246633.	1.1	6
216	Instrumented Objective Clinical Examination of Cerebellar Ataxia: the Upper and Lower Limbâ€”a Review. Cerebellum, 2021, , 1.	1.4	5
217	Longitudinal structural brain changes in Friedreich ataxia depend on disease severity: the IMAGE-FRDA study. Journal of Neurology, 2021, 268, 4178-4189.	1.8	8
218	Determining the Validity of Conducting Rating Scales in Friedreich Ataxia through Video. Movement Disorders Clinical Practice, 2021, 8, 688-693.	0.8	5

#	Article	IF	Citations
219	Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort. Annals of Clinical and Translational Neurology, 2021, 8, 1239-1250.	1.7	11
220	Results of a randomized doubleâ€blind study evaluating luvadaxistat in adults with Friedreich ataxia. Annals of Clinical and Translational Neurology, 2021, 8, 1343-1352.	1.7	9
221	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurology, The, 2021, 20, 362-372.	4.9	53
222	Development and Validation of a <scp>Patientâ€Reported</scp> Outcome Measure of Ataxia. Movement Disorders, 2021, 36, 2367-2377.	2.2	39
223	Quantitative Assessment of Friedreich Ataxia via Self-Drinking Activity. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 1985-1996.	3.9	5
224	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
225	Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis. Molecular Genetics and Metabolism, 2021, 133, 386-396.	0.5	12
226	Digital endpoints for selfâ€administered homeâ€based functional assessment in pediatric Friedreichâ€™s ataxia. Annals of Clinical and Translational Neurology, 2021, 8, 1845-1856.	1.7	11
227	Clinical Scales of Cerebellar Ataxias. , 2013, , 1783-1798.		3
228	Rehabilitation for ataxia study: protocol for a randomised controlled trial of an outpatient and supported home-based physiotherapy programme for people with hereditary cerebellar ataxia. BMJ Open, 2020, 10, e040230.	0.8	14
229	Ataxia. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 1208-1226.	0.4	52
230	Friedreichâ€™s ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. Aging, 2017, 9, 1440-1452.	1.4	29
231	Korean Version of the Scale for the Assessment and Rating of Ataxia in Ataxic Stroke Patients. Annals of Rehabilitation Medicine, 2014, 38, 742.	0.6	13
232	Ataxien: Assessment und Management. , 2010, , 293-303.		0
233	New advances in the treatment of Friedreich ataxia: promises and pitfalls. Clinical Investigation, 2011, 1, 1095-1106.	0.0	1
234	Rating Scales in Movement Disorders. , 2017, , 65-75.		4
236	Clinical Scales of Cerebellar Ataxias. , 2019, , 1-20.		0
237	Objective Assessment of Progression and Disease Characterization of Friedreich Ataxia via an Instrumented Drinking Cup: Preliminary Results. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2021, 29, 2365-2377.	2.7	4

#	Article	IF	Citations
238	Clinical Scales of Cerebellar Ataxias. , 2022, , 2033-2051.		0
239	The Responsiveness of Gait and Balance Outcomes to Disease Progression in Friedreich Ataxia. Cerebellum, 2022, 21, 963-975.	1.4	8
240	Artificial Intelligence for Dysarthria Assessment in Children With Ataxia: A Hierarchical Approach. IEEE Access, 2021, 9, 166720-166735.	2.6	4
242	Evolution of disability in spinocerebellar ataxias type 1, 2, 3, and 6. Annals of Clinical and Translational Neurology, 2022, 9, 286-295.	1.7	3
243	Remote Measurement of Functional Status in Pre-symptomatic and Symptomatic Individuals with Machado-Joseph Disease. Cerebellum, 2023, 22, 475-477.	1.4	2
244	Automatic Classification and Severity Estimation of Ataxia From Finger Tapping Videos. Frontiers in Neurology, 2021, 12, 795258.	1.1	6
251	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study. NeuroImage: Clinical, 2022, 34, 103025.	1.4	3
252	Detection of an Ataxia-type disease from EMG and IMU sensors. , 2022, , .		2
253	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	1.7	25
254	Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial. Neurotherapeutics, 2022, 19, 1259-1272.	2.1	21
257	Natural History of Friedreich Ataxia. Neurology, 2022, 99, .	1.5	21
258	Repeat expansion disorders. , 2023, , 293-312.		1
259	An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreichâ€™s ataxia. Nature Communications, 2022, 13, .	5.8	1
261	The S-Factor, a New Measure of Disease Severity in Spinocerebellar Ataxia: Findings and Implications. Cerebellum, 2023, 22, 790-809.	1.4	5
263	Clinical Motor Coordination Tests in Adult Neurology: A Scoping Review. Physiotherapy Canada Physiotherapie Canada, 0, , .	0.3	0
265	BiP inactivation due to loss of the deAMPylation function of FICD causes a motor neuron disease. Genetics in Medicine, 2022, 24, 2487-2500.	1.1	4
267	Spinal cord magnetic resonance imaging and spectroscopy detect early-stage alterations and disease progression in Friedreich ataxia. Brain Communications, 2022, 4, .	1.5	6
269	Progressive Spinal Cord Degeneration in Friedreich's Ataxia: Results from <scp>ENIGMAâ€Ataxia</scp>. Movement Disorders, 2023, 38, 45-56.	2.2	4

#	Article	IF	Citations
270	Practical recommendations for the clinical evaluation of patients with hereditary ataxia and hereditary spastic paraplegia. NeurologÃa (English Edition), 2022, , .	0.2	0
271	Prediction of the disease course in Friedreich ataxia. Scientific Reports, 2022, 12, .	1.6	2
272	Patient-Reported Impact of Symptoms in Friedreich Ataxia. Neurology, 2023, 100, e808-e821.	1.5	4
273	Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers. Movement Disorders, 2023, 38, 959-969.	2.2	3
274	A natural history study to track brain and spinal cord changes in individuals with Friedreichâ€™s ataxia: TRACK-FA study protocol. PLoS ONE, 2022, 17, e0269649.	1.1	3
275	Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia. Journal of Neurology, 2023, 270, 1615-1623.	1.8	4
276	Ataxia Rating Scales: Content Analysis by Linking to the International Classification of Functioning, Disability and Health. Healthcare (Switzerland), 2022, 10, 2459.	1.0	1
277	The Homogeneous Azorean Machado-Joseph Disease Cohort: Characterization and Contributions to Advances in Research. Biomedicines, 2023, 11, 247.	1.4	1
278	Quantitative Oculomotor Assessment in Hereditary Ataxia: Discriminatory Power, Correlation with Severity Measures, and Recommended Parameters for Specific Genotypes. Cerebellum, 2024, 23, 121-135.	1.4	3
279	Toward the Definition of Patient-Reported Outcome Measurements in Hereditary Spastic Paraplegia. Neurology: Genetics, 2023, 9, .	0.9	3
280	Technological Evolution in the Instrumentation of Ataxia Severity Measurement. IEEE Access, 2023, 11, 14006-14027.	2.6	1
281	A wearable motion capture suit and machine learning predict disease progression in Friedreichâ€™s ataxia. Nature Medicine, 2023, 29, 86-94.	15.2	20
283	Auditory neuropathy in mice and humans with Friedreich ataxia. Annals of Clinical and Translational Neurology, 2023, 10, 953-963.	1.7	1
285	Ataxia Scales for the Clinical Evaluation. , 2023, , 493-500.		0
286	Rehabilitation in ataxia. Indian Journal of Physical Medicine and Rehabilitation, 2023, 33, 21.	0.1	0
287	Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance. Cerebellum, 0, , .	1.4	5
289	Clinical Rating Scales for Ataxia. Contemporary Clinical Neuroscience, 2023, , 317-345.	0.3	0
299	Pre-Validation of a Virtual Reality Tool to Quantify the Severity of Friedreich's Ataxia. , 2023, , .		0

#	Article	IF	Citations
302	Quantitative Gait and Balance Outcomes for Ataxia Trials: Consensus Recommendations by the Ataxia Global Initiative Working Group on Digital-Motor Biomarkers. Cerebellum, 0, , .	1.4	3
307	A Novel Feature from Instrumented Utensils for Clinical Assessment of Friedreich Ataxia. , 2023, , .		0
313	Introductory Chapter: Insights into Ataxia. , 0, , .		0